Mestinon (Pyridostigmine Bromide)

Pyridostigmine bromide blocks the enzyme acetylcholinesterase, which normally breaks down acetylcholine at nerve‑muscle junctions. By inhibiting this enzyme, the drug raises acetylcholine levels, allowing more frequent activation of nicotinic receptors and improving muscle contraction.

The specific dose of Mestinon is individualized by the prescribing clinician based on the patient’s condition, severity, age, renal function, and response to therapy. Dosage adjustments are made to achieve optimal clinical benefit while minimizing side effects.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mestinon belongs to the acetylcholinesterase inhibitor class, which directly increases acetylcholine at the neuromuscular junction. Unlike anticholinergic agents that reduce muscle activity, pyridostigmine enhances transmission, making it the preferred option for conditions like myasthenia gravis where boosting muscle strength is required.

Mestinon tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mestinon is taken orally, usually as a tablet, with or without food as directed by the prescriber. The medication may be divided into multiple daily doses to maintain steady acetylcholine levels throughout the day.

Serious risks include cholinergic crisis, which can present as severe muscle weakness, respiratory depression, or bradycardia, and rare allergic reactions such as rash or angioedema. Prompt medical attention is required if any of these symptoms develop.

Mestinon is contraindicated in patients with known hypersensitivity to pyridostigmine or any component of the formulation, and it should be used with caution in individuals with severe asthma, chronic obstructive pulmonary disease, or significant cardiac conduction disorders.